欧州の希少疾患遺伝子検査市場：分析・予測 (2023-2033年)

欧州の希少疾患遺伝子検査の市場規模は、2023年の11億6,000万米ドルから、予測期間中は13.60%のCAGRで推移し、2033年には41億7,000万米ドルに達すると予測されています。

希少疾患遺伝子検査の市場は、これらの疾患の早期発見に対するニーズの高まりにより、顕著な成長を遂げています。希少疾患の発生が増加していることが、この成長軌道の極めて重要な要因となっています。さらに、特に世界の小児人口の間で、早期発見と予防に対する認識と関心が高まっており、これが市場成長をさらに促進すると予想されています。

当レポートでは、欧州の希少疾患遺伝子検査の市場を調査し、市場概要、主要動向、法規制環境、特許の動向、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・国別の詳細分析、主要企業のプロファイルなどをまとめています。

市場の分類：

セグメンテーション1：疾患タイプ別

• 消化器疾患
• 内分泌・代謝疾患
• 心血管疾患
• 神経疾患
• 血液・腫瘍疾患
• 皮膚科疾患
• その他

セグメンテーション2：技術別

• サンガーシーケンシング
• PCR
• NGS
• マイクロアレイ
• その他（ターゲット細胞遺伝学、核型分析、FISH）

セグメンテーション3：国別

• ドイツ
• 英国
• フランス
• イタリア
• ロシア
• スペイン
• その他

主要企業：

• CENTOGENE N.V.
• Eurofins Scientific SE
• QIAGEN N.V.

目次

エグゼクティブサマリー

調査範囲

第1章 市場

• 世界市場の展望
  • 製品の定義
  • 包含基準と除外基準
  • 市場概要
  • COVID-19による市場への影響
• 業界分析
  • 規制の枠組み
  • 特許分析
  • 資金調達シナリオ
• 市場力学
  • 概要
  • 市場促進要因
  • 市場の課題
  • 市場機会

第2章 欧州

• 欧州の希少疾患遺伝子検査市場
  • 市場力学
  • 市場規模・予測

第3章 企業プロファイル

List of Figures

• Figure 1: Global Prevalence Rare Disease, 2022
• Figure 2: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 3: Europe Rare Disease Genetic Testing Market, Market Dynamics
• Figure 4: Most Frequently Studied Rare Diseases, 2021
• Figure 5: Europe Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
• Figure 6: Europe Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
• Figure 7: Rare Disease Genetic Testing Market (by Region), $Billion, 2022 and 2033
• Figure 8: Share of Key Developments and Strategies, January 2019-June 2023
• Figure 9: Rare Disease Genetic Testing Market: Research Methodology
• Figure 10: Primary Research Methodology
• Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 12: Top-Down Approach (Segment-Wise Analysis)
• Figure 13: Europe Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
• Figure 14: Regulatory Scenario in Europe (by Country)
• Figure 15: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
• Figure 16: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
• Figure 17: NIH Funding on Rare Diseases, $Million, 2013-2023
• Figure 18: Rare Disease Genetic Testing Market Dynamics
• Figure 19: Rare Disease Prevalence in India, 2022
• Figure 20: Global Prevalence of Rare Diseases, 2022
• Figure 21: Most Frequently Studied Rare Diseases, 2021
• Figure 22: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
• Figure 23: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
• Figure 24: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 25: Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 26: Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 27: Europe Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 28: Germany Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 29: Germany Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 30: Germany Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 31: U.K. Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 32: U.K. Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 33: U.K. Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 34: France Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 35: France Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 36: France Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 37: Italy Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 38: Italy Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 39: Italy Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 40: Spain Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 41: Spain Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 42: Spain Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 43: Russia Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 44: Russia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 45: Russia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 46: Rest-of-Europe Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 47: Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 48: Rest-of-Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 49: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
• Figure 50: CENTOGENE N.V.: Product Portfolio
• Figure 51: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
• Figure 52: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 53: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2020-2022
• Figure 54: CENTOGENE N.V.: R&D Expenditure, $Million, 2020-202
• Figure 55: Eurofins Scientific SE: Product Portfolio
• Figure 56: Eurofins Scientific SE: Overall Financials, $Million, 2020-2022
• Figure 57: Eurofins Scientific SE: Net Revenue (by Segment), $Million, 2020-2022
• Figure 58: Eurofins Scientific SE: Net Revenue (by Region), $Million, 2020-2022
• Figure 59: QIAGEN N.V.: Product Portfolio
• Figure 60: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
• Figure 61: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
• Figure 62: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
• Figure 63: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Funding for Rare Disease Research
• Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
• Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
• Table 5: Europe Rare Disease Genetic Testing Market, Impact Analysis

Introduction to Europe Rare Disease Genetic Testing Market

The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033. The market for genetic testing in rare diseases has experienced notable growth, driven by a rising need for early identification of such conditions. The growing occurrence of rare diseases has been a pivotal factor in this growth trajectory. Moreover, there's a heightened acknowledgment and focus on early detection and prevention, particularly among pediatric populations worldwide, which is anticipated to further drive market growth.

Market Introduction

The Europe rare disease genetic testing market in Europe is witnessing substantial growth driven by several factors. Increasing awareness and advancements in genetic testing technologies have propelled demand for early detection and diagnosis of rare diseases across the continent. Additionally, the rising prevalence of rare diseases in European populations has contributed significantly to market growth. Moreover, there's a growing emphasis on early intervention and personalized medicine, further boosting the adoption of genetic testing for rare diseases. Regulatory initiatives and healthcare policies promoting accessibility to genetic testing services also play a crucial role in market development. As healthcare systems in Europe prioritize precision medicine and improved patient outcomes, the rare disease genetic testing market is poised for continued growth, offering opportunities for innovation and collaboration among stakeholders in the healthcare sector.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Russia
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• CENTOGENE N.V.
• Eurofins Scientific SE
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in the U.S.
    • 1.2.1.2 Legal Requirements and Framework in Europe
      • 1.2.1.2.1 U.K.
      • 1.2.1.2.2 Spain
    • 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.3.1 Japan
      • 1.2.1.3.2 China
      • 1.2.1.3.3 India
      • 1.2.1.3.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Europe

• 2.1 Europe Rare Disease Genetic Testing Market
  • 2.1.1 Market Dynamics
    • 2.1.1.1 Impact Analysis
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
    • 2.1.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
    • 2.1.2.3 Europe Rare Disease Genetic Testing Market (by Country)
      • 2.1.2.3.1 Germany
        • 2.1.2.3.1.1 Market Dynamics
        • 2.1.2.3.1.2 Market Size and Forecast
        • 2.1.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.2 U.K.
        • 2.1.2.3.2.1 Market Dynamics
        • 2.1.2.3.2.2 Market Size and Forecast
        • 2.1.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.3 France
        • 2.1.2.3.3.1 Market Dynamics
        • 2.1.2.3.3.2 Market Size and Forecast
        • 2.1.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.4 Italy
        • 2.1.2.3.4.1 Market Dynamics
        • 2.1.2.3.4.2 Market Size and Forecast
        • 2.1.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.5 Spain
        • 2.1.2.3.5.1 Market Dynamics
        • 2.1.2.3.5.2 Market Size and Forecast
        • 2.1.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.6 Russia
        • 2.1.2.3.6.1 Market Dynamics
        • 2.1.2.3.6.2 Market Size and Forecast
        • 2.1.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.7 Rest-of-Europe
        • 2.1.2.3.7.1 Market Dynamics
        • 2.1.2.3.7.2 Market Size and Forecast
        • 2.1.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

• 3.1 Overview
  • 3.1.1 CENTOGENE N.V.
    • 3.1.1.1 Company Overview
    • 3.1.1.2 Role of CENTOGENE N.V. in the Rare Disease Genetic Testing Market
    • 3.1.1.3 Financials
    • 3.1.1.4 Recent Developments
    • 3.1.1.5 Analyst Perspective
  • 3.1.2 Eurofins Scientific SE
    • 3.1.2.1 Company Overview
    • 3.1.2.2 Role of Eurofins Scientific SE in the Rare Disease Genetic Testing Market
    • 3.1.2.3 Financials
    • 3.1.2.4 Recent Developments
    • 3.1.2.5 Analyst Perspective
  • 3.1.3 QIAGEN N.V.
    • 3.1.3.1 Company Overview
    • 3.1.3.2 Role of QIAGEN N.V. in the Rare Disease Genetic Testing Market
    • 3.1.3.3 Financials
    • 3.1.3.4 Recent Developments
    • 3.1.3.5 Analyst Perspective